ClinicalTrials.gg
CompletedNCT06046391Updated Dec 15, 2025

Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult

A Phase 2 interventional study of LP-003 dose 1 and LP-003 dose 2 in Seasonal Allergic Rhinitis, sponsored by Longbio Pharma. Completed at 17 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Longbio Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Rhinitis, Allergic, Seasonal with a site in China — 12 open to participants now, 14 under way, 8 of them phase 3. Rhinitis, Allergic, Seasonal · China.

Enrollment
11th of 27
180 · median 160
Started
2023
with 2 others
Phase 2
12 of 27
5 open now
Registered
7th of 27
by date
Lead sponsor
2 of 27
Longbio Pharma

Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, this one is the 11th largest by enrollment, is one of 3 that started in 2023, is one of 12 in phase 2, and was the 7th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

12 of the 27 studies in Rhinitis, Allergic, Seasonal with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Rhinitis, Allergic, Seasonal with a site in China, or all of them as a file.
02

Study summary

Allergic rhinitis (AR) affects large population worldwide, the most commonly used medication include anti-histamine, nasal spray and anti-LTRAs inhibitors (leukotriene receptor antagonists), Even after those first-line treatment, there is still a large number of patient (\~20%) are not well/adequately controlled. Anti-IgE antibody has been approved to treat moderate to severe AR by PMDA/Japan in 2020, demonstrating the efficacy of IgE blockade in the treatment of allergic rhinitis. The current study presents a novel anti-IgE antibody (LP-003) with higher affinity to IgE, stronger efficacy and longer half-life.

Read the detailed description

The purpose of this study was to evaluate the efficacy and safety of LP-003 in combination with SoC (nasal corticosteroids and/or anti-histamine) in adult patients with Moderate to Severe Seasonal Allergic Rhinitis, whose symptoms were inadequately controlled despite the current recommended therapies (nasal corticosteroids and/or anti-histamine) in the previous 2 pollen seasons.

03

Conditions studied

  • Seasonal Allergic Rhinitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 65 years at the screening period
  2. Patients who met the diagnostic criteria of allergic rhinitis in Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (revised edition, 2022) : a. Clinical symptoms: more than 2 (including 2 items) symptoms of sneezing, rhinorrhea, nasal congestion, nasal itching and other symptoms appear, which last or accumulate for more than 1h per day and may be accompanied by ocular symptoms such as itchy eyes/ tearing/ redness and burning heat sensation; b. Physical signs: pale, edema of the nasal mucosa and nasal watery discharge; c. Allergen detection: positive of at least 1 allergen skin prick test(SPT) and/or serum-specific IgE within 1 year before enrollment, or nasal provocation test positive
  3. Had inadequately controlled symptoms (≥TNSS score of 6 and ≥ nasal congestion score of 2) of seasonal allergic rhinitis in last two years despite the use of nasal or in combination of one anti-histamine recommended by Guidelines.
  4. Having any nasal symptom last for at least 2 days or any nasal and eye symptom last for at least one day, and ≥TNSS score of 1
  5. Subjects (including partners) have no pregnancy and sperm, egg donation plan and voluntarily take one or more non-pharmaceutical measures for , such as complete abstinence, intrauterine ring, partner ligation at period from drug administration to 6 months after the last study drug administration
  6. voluntary participation in this trial and signing the form

Exclusion criteria

Exclusion Criteria:

  1. History of to any content of the study drugs or its ..
  2. Subjects with non-allergic rhinitis combined, such as drug rhinitis, vasomotor rhinitis, Nonallergic rhinitis with eosinophilia syndrome, acute and chronic sinusitis, rhinitis sicca anterior, atrophic rhinitis, obvious deviation of nasal septum
  3. Subjects with perennial allergic rhinitis ( except for seasonal allergic rhinitis combined with perennial allergic rhinitis, which get attacks seasonally )
  4. Subjects who have undergone nasal surgery or sinus surgery within 1 year before screening
  5. Subjects who suffer from glaucoma, cataracts, herpes simplex keratitis, infectious conjunctivitis or currently and other eye infections ( Except for allergic conjunctivitis )
  6. Subjects with active facial or systemic fungal, bacterial, viral or parasitic infection, and oral candida infection, who still require ongoing treatment
  7. With uncontrolled systemic disease (unstable ischemic heart disease, class III/IV left ventricular failure, arrhythmias, uncontrolled hypertension, cerebrovascular disease, neurodegenerative disease, other neurological disorders, uncontrolled hypothyroidism or hyperthyroidism and other disorders, hypokalemia, hyperadrenergic status, diagnosed as a in the past, except for basal cell carcinoma or squamous cell skin cancer ) ; History of myocardial infarction (MI) within 1 year prior to the screening
  8. In screening period: a) WBC \< 2.5×10\^9/L, b) or ALT > 2.0× or > 1.5×ULN, c) Cr > 1.5×ULN
  9. Subjects who have been treated by Omalizumab or other similar drugs within 6 months prior to the screening
  10. Subjects who have taken systemic within 4 weeks prior to the screening
  11. Subjects who have taken intranasal glucocorticoids, mast cell membrane stabilizers, tricyclic antidepressants, leukotriene receptor antagonists, antihistamines within 1 week prior to the screening
  12. Subjects who have taken traditional Chinese medicine for allergic rhinitis within 7 days prior to the screening
  13. Subjects who have received allergen immunotherapy within half of year prior to the screening (in treatment), or who have received allergen immunotherapy within 3 years prior to the screening ( completed treatment )
  14. During the study period, in addition to standard treatment concomitant drugs and salvage therapy drugs specified in the protocol. Subjects are prohibited from taking medications such as anticholinergics (oral and intranasal anticholinergics, including ipratropium nasal sprays), glucocorticoids, leukotriene receptor antagonists, antihistamines, mast cell membrane stabilizers, decongestants, nasal saline flushing, tricyclic antidepressants, antiallergic Chinese herbal medicines, , immunomodulators and immunotherapy
  15. Subjects with serious organic diseases such as heart, lung, liver, kidney
  16. Subjects with poor compliance, such as poor medication compliance, inability to fill in diary cards correctly, and use of prohibited medications
  17. Who combined with nerve and mental illness that could not or unwilling to follow the study, and with disabilities as prescribed by law (blind, deaf, mute, mentally disabled, mentally disabled, etc.)
  18. Who plan to travel to other regions in which there is no allergic pollen during the study period for more than two consecutive days or three accumulated days
  19. Pregnant or lactating women and women who plan pregnancy
  20. Participated in other clinical studies within 3 months prior to the start of the study
  21. Any condition that the investigator or primary physician believes may not be appropriate for participating the study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    LP-003 dose 1

    Eligible patients randomized to this arm received LP-003 subcutaneously for 8 weeks

    Biological: LP-003 dose 1

  • Experimental
    LP-003 dose 2

    Eligible patients randomized to this arm received LP-003 subcutaneously for 8 weeks

    Biological: LP-003 dose 2

  • Placebo comparator
    Placebo

    Eligible patients randomized to this arm received placebo subcutaneously for 8 weeks

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean nasal symptom score

    Nasal symptoms (itchy, sneezing, rhinorrhea and nasal congestion) were recorded by the patient everyday in their e-Diary, on a scale of 0 (none) to 3 (intense/severe). Nasal symptom score (0-12 point) consisted of score for severity of itchy (0-3 point), sneezing (0-3 point), rhinorrhea (0-3 point) and nasal congestion (0-3 point). Peak pollen period was defined as the period between the first and last three consecutive days with ≥300 total pollen/1000 mm2 each day.

    Time frame: peak pollen period(estimated average 4 weeks)

Secondary outcomes

  1. Daily nasal symptom medication score

    The daily nasal symptom medication score consisted of the sum of the daily nasal symptom severity score (0-12 points) and the daily nasal rescue medication score.

    Time frame: peak pollen period(estimated average 4 weeks)

  2. Daily nasal symptom medication score

    The daily nasal symptom medication score consisted of the sum of the daily nasal symptom severity score (0-12 points) and the daily nasal rescue medication score. Pollen period was defined as the period between the first day when the total daily pollen count was ≥80 total pollen/1000 mm2 to the first day when the total daily pollen count was \<80 total pollen/1000 mm2

    Time frame: pollen period(estimated average 10 weeks)

  3. Daily ocular symptom medication score

    Ocular symptoms (itchy eyes/foreign body sensation/redness, tearing) were recorded by the patient everyday in their e-Diary, on a scale of 0 (none) to 3 (intense/severe). Ocular symptom score (0-6 point) consisted of score for severity of itchy eyes/foreign body sensation/redness (0-3 point) and tearing (0-3 point). The daily ocular symptom medication score consisted of the sum of the daily ocular symptom severity score (0-6 points) and the daily ocular rescue medication score.

    Time frame: pollen period(estimated average 10 weeks)

07

Study locations

17 sites
  • Beijing Shijitan Hospital
    Beijing, Beijing Municipality 100038, China
  • Dongfang Hospital
    Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality, China
  • Zhengzhou central hospital
    Zhengzhou, Henan, China
  • Changchun University of Chinese Medicine Affiliated Hospital
    Changchun, Jilin, China
  • Tonghua central hospital
    Tonghua, Jilin, China
  • Yan Bian Chao Yi Hospital
    Yanbian, Jilin, China
  • Yanbian University hospital
    Yanji, Jilin, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning, China
  • Yinchuan Peoples Hospital
    Yinchuan, Ningxia, China
  • Zibo central hospital
    Zibo, Shandong, China
  • Linfen Peoples Hospital
    Linfen, Shanxi, China
  • Second hospital of Shanxi Medical University University
    Taiyuan, Shanxi, China
  • The First Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • Xidian group hospital
    Xi’an, Shanxi, China
  • Tianjin Peoples Hospital
    Tianjing, Tianjing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Oct 2023, 3 months.

Of 24 phase 2 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Sep 21, 2023
StartActual
Jul 6, 2023
Primary completionActual
Oct 19, 2023
CompletionActual
Aug 6, 2024
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06046391
Lead sponsor
Longbio Pharma
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Jul 6, 2023
Primary completion
Oct 19, 2023
Completion
Aug 6, 2024
Last update
Dec 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LP-003

Start the discussion